On the basis of our results, we also propose that pharmacological modulation of FAK activity could provide an approach to boost imatinib and nilotinib efficacy and limit resistance to these drugs in CML & GIST and other cancers in which imatinib is used, a possibility that warrants further investigation. Here, PTK2 is linked to cancer.